“Gepants” cgpr antagonist – a NEW clinical approach to treat migraine and neuropeptides
Abstract
The present review is devoted to apparent part of CGRP in migraine pathogenesis and to depict the various treatment modalities that are presently available to target this neuropeptide. A veritably incapacitating neurovascular illness, migraines are typified by excruciating headaches that are accompanied by nausea, photophobia, and/or phonophobia, as well as activation of the trigeminovascular system by the production of calcitonin-gene related peptide (CGRP). Zavegepant through nasal drug delivery system is one of the best approaches which used as a target drug delivery in sustained controlled release fashion. The main advantage to choose the nasal route for drug delivery is to bypass the first hepatic metabolism and direct absorption of drug into the systemic circulation. To provide a relevant background, a brief discussion of CGRP antagonist and FDA approved drugs for migraine treatment will also be considered in this review.
Read the paper
Related studies
- Calcium Ions in the Physiology and Pathology of the Central Nervous System
- AI-powered in silico twins: redefining precision medicine through simulation, personalization, and predictive healthcare
- In silico functional, structural and pathogenicity analysis of missense single nucleotide polymorphisms in human MCM6 gene
- In Silico drug repurposing pipeline using deep learning and structure based approaches in epilepsy
- Targeting serotonin receptors with phytochemicals – an in-silico study
- In silico exploration of anti-prostate cancer compounds from differential expressed genes
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.